Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial

CONTEXT Neurocognitive impairment in schizophrenia is severe and is an important predictor of functional outcome. The relative effect of the second-generation (atypical) antipsychotic drugs and older agents on neurocognition has not been comprehensively determined. OBJECTIVE To compare the neurocogn...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Archives of general psychiatry 2007-06, Vol.64 (6), p.633-647
Hauptverfasser:	Keefe, Richard S. E, Bilder, Robert M, Davis, Sonia M, Harvey, Philip D, Palmer, Barton W, Gold, James M, Meltzer, Herbert Y, Green, Michael F, Capuano, George, Stroup, T. Scott, McEvoy, Joseph P, Swartz, Marvin S, Rosenheck, Robert A, Perkins, Diana O, Davis, Clarence E, Hsiao, John K, Lieberman, Jeffrey A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Adult and adolescent clinical studies Antipsychotic Agents - therapeutic use Benzodiazepines - therapeutic use Biological and medical sciences Cognition Disorders - diagnosis Cognition Disorders - drug therapy Cognition Disorders - psychology Cohort Studies Dibenzothiazepines - therapeutic use Double-Blind Method Female Humans Male Medical sciences Neuropharmacology Neuropsychological Tests - statistics & numerical data Perphenazine - therapeutic use Pharmacology. Drug treatments Piperazines - therapeutic use Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Psychoses Quetiapine Fumarate Risperidone - therapeutic use Schizophrenia Schizophrenia - diagnosis Schizophrenia - drug therapy Schizophrenic Psychology Thiazoles - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!